二甲双胍对肥胖及非肥胖PCOS妇女内分泌的影响

目的:分析肥胖及非肥胖多囊卵巢综合征(PCOS)患者的内分泌特征,探讨应用二甲双胍治疗对两类患者临床症状及内分泌指标的影响。方法:按体重指数(BMI)将43例PCOS患者分为肥胖组23例,非PCOS肥胖组20例,比较BMI、FPG、FINS及FSH、LH及T;两组均服用二甲双胍3个月,观察治疗前后临床症状及内分泌指标的改善情况。结果:肥胖组BMI、FINS及HOMA-IR明显高于非肥胖组(P<0.01),而非肥胖组LH高于肥胖组(P<0.05)。二甲双胍治疗后肥胖组BMI降低(P<0.01),FSH升高(P<0.05),LH、FPG、FINS和HOMA-IR均明显降低(P<0.01)。而非肥胖组BMI及FPG无改变。结论:肥胖与非肥胖PCOS患者内分泌特征不同,二甲双胍可明显改善肥胖及非肥胖PCOS患者的临床症状和内分泌指标,尤其适用于肥胖PCOS患者。

Efficacy of Metformin in Obese and Non-obese Women with Polycystic Ovary Syndrome

Objective:To analyze the endocritic profiles of obese and non-obese women with polycystic ovary syndrome(PCOS),and study the effects of metformin on those patients.Methods:Forty-three women with PCOS were divided into two groups depend on BMI which were obese group and non-obese group,and were treated with metformin for three months.Body mass index(BMI),the situation of menstruation cycle,the degree of acne,Ferriman-Gallwey score,as well as gonadotropine(FSH,LH),testosterone(T),fasting insuline,fasting plasma glucose and HOMA-IR were measured in all patients before and after treatment.Results:The levels of BMI,FINS and HOMA-IR were significantly higher in obese group than those in non-obese group(P<0.01),while LH level was higher in non-obese group than that in obese group(P<0.05).After three months of treatment,in obese group,BMI level was decreased but FSH level was increased(P<0.05),and the levels of LH,FPG,FINS and HOMA-IR were decreased in different degrees(P<0.01),but BMI and FPG levels were showed no significant changes in non-obese group.Conclusion:Endocritic profiles in obese PCOS patients are different from those in non-obese PCOS patients,and metformin are effective on patients with obese or non-obese PCOS,especially applicable to obese PCOS patients.